Christopher M. McBride

Design, Structure−Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors

Paul A. Renhowe, Sabina Pecchi, Cynthia M. Shafer et al. · Journal of Medicinal Chemistry · 2008 · 134 citations · Full text

Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors

Savithri Ramurthy, Sharadha Subramanian, Mina Aikawa et al. · Journal of Medicinal Chemistry · 2008 · 76 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Pharmaceutical Science +13

Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma

Teresa E. Williams, Sharadha Subramanian, Joelle Verhagen et al. · ACS Medicinal Chemistry Letters · 2015 · 53 citations · Full text

Medicinal Chemistry, Drug Target, Oncology +15

Design and structure–activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases

Christopher M. McBride, Paul A. Renhowe, Carla Heise et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 45 citations · Full text

Structure–activity Relationship, Molecular Pharmacology, Medicinal Chemistry +13

Design, Structure–Activity Relationship, and in Vivo Characterization of the Development Candidate NVP-HSP990

Christopher M. McBride, Barry H. Levine, Yi Xia et al. · Journal of Medicinal Chemistry · 2014 · 27 citations · Full text

Structure–activity Relationship, Pharmaceutical Science, Commercial Hit +16